[6-K] Canaan Inc. American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Immuneering Corporation (IMRX) – Form 4 insider transaction

Director Diana F. Hausman disclosed two open-market purchases executed on 07/02/2025:

• 2,500 Class A common shares acquired directly at $3.5956 per share.
• 3,000 Class A common shares acquired indirectly through a spouse at $3.6245 per share.

Post-transaction beneficial ownership stands at 2,500 shares held directly and 3,000 shares held indirectly, for a combined total of 5,500 shares. No derivative securities were involved and no shares were sold. The filing was signed on 07/07/2025.

Positive

• Director bought 5,500 shares on the open market, showing incremental insider confidence.

Negative

• Purchase size is small relative to Immuneering’s total share count, implying limited market impact.

Insights

Securities Analyst

TL;DR – Small open-market insider buy; positive sentiment signal but immaterial to overall float or valuation.

Director purchases generally indicate insider confidence. Hausman’s acquisition of 5,500 shares at an average price of roughly $3.61 suggests personal conviction in Immuneering’s prospects. However, the dollar value is modest and represents a negligible percentage of outstanding shares, limiting its fundamental impact. No sales or derivative hedges accompany the trade, so the transaction is a straightforward long equity position. For investors, the filing is a mild positive sentiment cue rather than a catalyst likely to affect valuation.

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2025

 

Commission File Number: 001-39127

 

 

 

Canaan Inc.

 

 

 

28 Ayer Rajah Crescent

#06-08

Singapore 139959

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

Exhibit Index

 

Exhibit No.	 	Description
 	 	 
Exhibit 99.1	 	Canaan Inc. Provides June 2025 Bitcoin Production and Mining Operation Updates

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	Canaan Inc.
 	 
 	By:	/s/ Nangeng Zhang
 	 
 	Name:	Nangeng Zhang
 	Title:	Chairman and Chief Executive Officer

 

Date: July 7, 2025

 

 

 

FAQ

How many IMRX shares did Director Diana Hausman purchase?

She bought 5,500 Class A common shares on 07/02/2025.

What prices were paid for the IMRX shares?

Shares were purchased at $3.5956 and $3.6245 per share.

What is Diana Hausman’s total IMRX ownership after the transaction?

She now beneficially owns 5,500 shares (2,500 directly and 3,000 indirectly via spouse).

Were any IMRX shares sold in this Form 4 filing?

No. The filing reports only purchases; there were no sales.

Did the filing include any derivative securities?

No derivative securities were reported in Table II.